Literature DB >> 28008196

Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients.

Satomi Hattori1, Hiroaki Kajiyama2, Utako Fuji1, Yuko Furui1, Yuki Ishibashi1, Yuka Hattori1, Noriko Takahashi1, Fumitaka Kikkawa2, Toshiya Misawa1.   

Abstract

Primary peritoneal carcinoma (PPC) is treated similarly to advanced epithelial ovarian carcinoma (aEOC); however, the standard approach for the management of PPC is controversial. The objective of this study was to evaluate the clinical features and prognosis of those patients. A retrospective analysis was performed of eight patients with PPC between January 2008 and December 2015. Clinicopathologic parameters, the diagnostic modality, treatment, and oncologic outcome were analyzed. The median age at the time of diagnosis was 72.5 years (range: 55-79), with a median follow-up of 26.5 months (range, 5-74). Most of the PPC developed with carcinomatosis peritonei involving ascites, while some cases developed sporadically in the peritoneal or extraperitoneal cavity without ascites. The most common initial symptom was abdominal fullness, and other symptoms were inguinal tumor, paralysis of the extremities, and respiratory disorder. The preoperative CA125 value was elevated in all patients. In four patients who did not undergo primary surgery, the final diagnoses were determined by the ascites cytology and radiological image. Initial or interval debulking surgery was performed in only two patients. All patients were treated with paclitaxel or docetaxel plus carboplatin. Five showed a complete response (CR), and one showed a partial response (PR). Among the five patients with CR, the median progression-free and overall survival periods were 15 (12-26) and 41.5 (32-74) months, respectively. Three patients without carcinomatosis peritonei showed a relatively favorable prognosis. The management of PPC is generally consistent with that of aEOC; however, in atypical cases, the treatment method should be considered individually.

Entities:  

Keywords:  Primary peritoneal carcinoma; clinical outcome; diagnosis; peritoneal metastasis

Year:  2016        PMID: 28008196      PMCID: PMC5159466          DOI: 10.18999/nagjms.78.4.407

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  15 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer.

Authors:  G H Eltabbakh; M S Piver; N Natarajan; C J Mettlin
Journal:  Obstet Gynecol       Date:  1998-02       Impact factor: 7.661

3.  Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?

Authors:  A Ayhan; C Taskiran; N Yigit-Celik; G Bozdag; M Gultekin; A Usubutun; N Guler; K Yuce
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

4.  Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum.

Authors:  L W Huang; A P Garrett; M G Muto; C V Colitti; D A Bell; W R Welch; R S Berkowitz; S C Mok
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

5.  Primary peritoneal serous papillary carcinoma presenting as a large mesenteric mass mistaken for ovarian cancer: a case of primary peritoneal carcinoma.

Authors:  Ji Woo Kim; Hwa Sun Lee; Kyu Sik Shin; Young Ho Gam; Kyung Don Baik
Journal:  Obstet Gynecol Sci       Date:  2015-05-19

6.  Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.

Authors:  G Dubernard; P Morice; A Rey; S Camatte; V Fourchotte; A Thoury; C Pomel; P Pautier; C Lhommé; P Duvillard; D Castaigne
Journal:  Eur J Surg Oncol       Date:  2004-11       Impact factor: 4.424

7.  Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.

Authors:  Takashi Onda; Hiroaki Kobayashi; Toru Nakanishi; Masayuki Hatae; Tsuyoshi Iwasaka; Ikuo Konishi; Taro Shibata; Haruhiko Fukuda; Toshiharu Kamura; Hiroyuki Yoshikawa
Journal:  Gynecol Oncol       Date:  2009-01-31       Impact factor: 5.482

8.  Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.

Authors:  J D Bloss; S Y Liao; R E Buller; A Manetta; M L Berman; S McMeekin; L P Bloss; P J DiSaia
Journal:  Gynecol Oncol       Date:  1993-09       Impact factor: 5.482

9.  Primary Peritoneal Carcinoma Initially Presenting as Atypical Cervical Lymphadenopathy.

Authors:  Yun Mi Kim; Yeong Min Lee; Si Hyeing Lee; Dong Woo Lee; Ki Hyang Kim
Journal:  Case Rep Oncol       Date:  2015-05-28

10.  Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity.

Authors:  I Otsuka; S Kameda; K Hoshi
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

View more
  2 in total

1.  Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge.

Authors:  Mariam Shabbir; Sonu Sahni; Meena Ahluwalia; Raji Ayinla
Journal:  Cureus       Date:  2022-05-17

2.  Literature-Wide Association Studies (LWAS) for a Rare Disease: Drug Repurposing for Inflammatory Breast Cancer.

Authors:  Xiaojia Ji; Chunming Jin; Xialan Dong; Maria S Dixon; Kevin P Williams; Weifan Zheng
Journal:  Molecules       Date:  2020-08-28       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.